29 June 2023>: Articles
Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare coexistence of disease or pathology
Christopher R. Grant A* , Elaine J. Chiao E , Zhaohui L. Arter A , Cary Johnson C , Truc Tran B , Farshid Dayyani E , Krishnansu Tewari E , Valery Vilchez E , Joeseph Carmichael E , May Cho ADOI: 10.12659/AJCR.939448
Am J Case Rep 2023; 24:e939448
Figure 2. Signatera residual disease testing demonstrating before and after the use of pembrolizumab.